FI111806B - Farmaceutiska kompositioner - Google Patents
Farmaceutiska kompositioner Download PDFInfo
- Publication number
- FI111806B FI111806B FI20001749A FI20001749A FI111806B FI 111806 B FI111806 B FI 111806B FI 20001749 A FI20001749 A FI 20001749A FI 20001749 A FI20001749 A FI 20001749A FI 111806 B FI111806 B FI 111806B
- Authority
- FI
- Finland
- Prior art keywords
- pharmaceutical composition
- phosphate
- composition according
- active ingredient
- salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (21)
1. Farmaceutisk komposition, kännetecknad därav, att däri ingär (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metylsulfonyl)amino]- 5 pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxihept-6-ensyra eller ett farmaceutiskt godtagbart sait därav som aktiv bestandsdel och ett tribasiskt fosfatsalt, där katjonen ärflervärd.
2. Farmaceutisk komposition enligt patentkrav 1, kännetecknad därav, att det tribasiska fosfatsaltet, där katjonen är flervärd, är valt 10 bland tribasiskt kalciumfosfat, tribasiskt magnesiumfosfat och tribasiskt alumi-niumfosfat.
3. Farmaceutisk komposition enligt patentkrav 1 eller 2, kännetecknad därav, att det tribasiska fosfatsaltet, där katjonen är flervärd, är tribasiskt kalciumfosfat.
4. Farmaceutisk komposition enligt nagot av patentkraven 1-3, kännetecknad därav, att det tribasiska fosfatsaltets viktförhällande tili den aktiva beständsdelen är 1:80 - 50:1.
5. Farmaceutisk komposition enligt nägot av föregaende patentkrav, kännetecknad därav, att däri ytterligare ingär ett eller flera fyllmedel, 20 bindemedel, disintegreringsmedel eller smörjmedel.
6. Farmaceutisk komposition för oral administrering, kännetecknad därav, att däri ingär (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2- ..il’ [metyl(metylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxihept-6-ensyra f*.. eller ett farmaceutiskt godtagbart sait därav som aktiv bestandsdel, ett eller fle- ·:··: 25 ra fyllmedel, ett eller flera bindemedel, ett eller flera disintegreringsmedel, ett eller flera smörjmedel och ett tribasiskt fosfatsalt, där katjonen är flervärd. * > ·
7. Farmaceutisk komposition enligt patentkrav 6, känneteck- • · · n a d därav, att den aktiva beständsdelen är närvarande i en mängd av .. §. t 1 - 80 % av kompositionens vikt. • I
8. Farmaceutisk komposition enligt patentkrav 6 eller 7, k ä n n e- • * tecknad därav, att det tribasiska fosfatsaltet är närvarande i en mängd av 1 - 50 % av kompositionens vikt.
9. Farmaceutisk komposition enligt patentkrav 6, 7 eller 8, k ä n n e-tecknad därav, att fyllmedlet är närvarande i en mängd av 30 - 90 % av f · · '. . 35 kompositionens vikt. » # is 111806
10. Farmaceutisk komposition enligt nägot av patentkraven 6-9, kännetecknad därav, att bindemedlet är närvarande i en mängd av 2-90 % av kompositionens vikt.
11. Farmaceutisk komposition enligt nägot av patentkraven 6-10, 5 kännetecknad därav, att disintegreringsmedlet är närvarande i en mängd av 2 - 10 % av kompositionens vikt.
12. Farmaceutisk komposition enligt nägot av patentkraven 6-11, kännetecknad därav, att smörjmedlet är närvarande i en mängd av 0,5 - 3 vikt-%.
13. Farmaceutisk komposition enligt patentkrav 6, känneteck nad därav, att däri ingär (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metyl-sulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxihept-6-ensyra eller ett farmaceutiskt godtagbart sait därav som aktiv beständsdel, tribasiskt kalcium-fosfat, mikrokristallin cellulosa, laktos, natriumstärkelseglykollat, butylerad hyd-15 roxitoluen och magnesiumstearat.
14. Farmaceutisk komposition enligt patentkrav 6, kännetecknad därav, att däri ingär (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl- (metylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxihept-6-ensyra eller ett farmaceutiskt godtagbart sait därav som aktiv beständsdel, tribasiskt kal-20 ciumfosfat, povidon, mikrokristallin cellulosa, mannitol, natriumstärkelseglykollat, butylerad hydroxitoluen och magnesiumstearat.
, : 15. Farmaceutisk komposition enligt patentkrav 6, känneteck- n a d därav, att däri ingär (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl- (metylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxihept-6-ensyra eller • ;..j 25 ett farmaceutiskt godtagbart sait därav som aktiv beständsdel, tribasiskt kal- .···. ciumfosfat, cros-povidon, mikrokristallin cellulosa, laktos och magnesiumstea- ,···, rat.
16. Farmaceutisk komposition enligt patentkrav 6, känneteck- .. . n a d därav, att däri ingär (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl- 30 (metylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxihept-6-ensyra eller • · '·;·* ett farmaceutiskt godtagbart sait därav som aktiv beständsdel, tribasiskt kal- : ciumfosfat, povidon, mikrokristallin cellulosa, laktos, natriumstärkelseglykollat, :1 “; butylerad hydroxitoluen och magnesiumstearat.
17. Farmaceutisk komposition enligt nägot av föregäende patent-35 krav, kännetecknad därav, att den aktiva beständsdelen däri är kai- » » » » I 14 111806 ciumsaltet av (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metylsulfonyl)-amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydiOxihept-6-ensyra.
18. Användning av ett tribasiskt fosfatsalt, där katjonen är flervärd, för stabilisering av (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metylsulfo- 5 nyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxihept-6-ensyra eller ett farma-ceutiskt godtagbart sait därav.
19. Användning enligt patentkrav 18, kännetecknad därav, att det tribasiska fosfatsaltet, där katjonen är flervärd, är valt bland tribasiskt kalciumfosfat, tribasiskt magnesiumfosfat och tribasiskt aluminiumfosfat.
20. Användning enligt patentkrav 18 eller 19, kän-netecknad därav, att det tribasiska fosfatsaltet, där katjonen är flervärd, är tribasiskt kalciumfosfat.
21 Förfarande för framställning av en stabilserad farmaceutisk komposition, kännetecknat därav, att ett tribasiskt fosfatsalt, där katjonen 15 är flervärd, inkorporeras i en farmaceutisk komposition, som innehäller fö-reningen (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metylsulfonyl)amino]-pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxihept-6-ensyra eller ett farmaceutiskt godtagbart sait därav. • 4 · > · · • l I * * 4 « · < f 1si • » I « 1 I · • · 1 • · • · • · I at > • 1 1 • I I I • I • I 1 • t i • » I t t 1 • I < • » • · * » a » ia • i « » I a
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0001621 | 2000-01-26 | ||
GBGB0001621.2A GB0001621D0 (en) | 2000-01-26 | 2000-01-26 | Pharmaceutical compositions |
Publications (3)
Publication Number | Publication Date |
---|---|
FI20001749A0 FI20001749A0 (sv) | 2000-08-04 |
FI20001749A FI20001749A (sv) | 2001-07-27 |
FI111806B true FI111806B (sv) | 2003-09-30 |
Family
ID=9884259
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI20001750A FI121365B (sv) | 2000-01-26 | 2000-08-04 | Farmaceutisk komposition, som omfattar (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxi-6-heptensyra och förfarande för framställning därav |
FI20001749A FI111806B (sv) | 2000-01-26 | 2000-08-04 | Farmaceutiska kompositioner |
FI20105657A FI121589B (sv) | 2000-01-26 | 2010-06-10 | Farmaceutisk sammansättning som omfattar (E)-7[4-(4-fluorofenyl)-6-isopropyl-2[metyl(metylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxi-6-heptensyra |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI20001750A FI121365B (sv) | 2000-01-26 | 2000-08-04 | Farmaceutisk komposition, som omfattar (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl(metylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxi-6-heptensyra och förfarande för framställning därav |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI20105657A FI121589B (sv) | 2000-01-26 | 2010-06-10 | Farmaceutisk sammansättning som omfattar (E)-7[4-(4-fluorofenyl)-6-isopropyl-2[metyl(metylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxi-6-heptensyra |
Country Status (48)
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0001621D0 (en) | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
GB0003305D0 (en) * | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
USRE44578E1 (en) | 2000-04-10 | 2013-11-05 | Teva Pharmaceutical Industries, Ltd. | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
DK2382970T3 (da) † | 2000-04-10 | 2013-03-25 | Teva Pharma | Stabile farmaceutiske sammensætninger, der indeholder 7-substitueret-3,5-dihydroxyheptansyrer eller 7-substitueret-3,5-dihydroxyheptensyrer |
NZ535261A (en) * | 2000-08-08 | 2004-12-24 | Smithkline Beecham P | A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide |
GB0028429D0 (en) * | 2000-11-22 | 2001-01-10 | Astrazeneca Ab | Therapy |
EP1911462A3 (en) * | 2001-01-26 | 2011-11-30 | Schering Corporation | Compositions comprising a sterol absorption inhibitor |
US7842308B2 (en) * | 2001-01-30 | 2010-11-30 | Smithkline Beecham Limited | Pharmaceutical formulation |
US7883721B2 (en) * | 2001-01-30 | 2011-02-08 | Smithkline Beecham Limited | Pharmaceutical formulation |
GB0102342D0 (en) * | 2001-01-30 | 2001-03-14 | Smithkline Beecham Plc | Pharmaceutical formulation |
US20050175687A1 (en) * | 2001-01-30 | 2005-08-11 | Mcallister Stephen M. | Pharmaceutical formulations |
KR20040026705A (ko) | 2001-08-16 | 2004-03-31 | 테바 파마슈티컬 인더스트리즈 리미티드 | 스타틴의 칼슘 염 형태의 제조 방법 |
WO2004016262A1 (ja) * | 2002-08-12 | 2004-02-26 | Kyowa Hakko Kogyo Co., Ltd. | アミノ酸含有チュアブル錠 |
GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
US20060019269A1 (en) * | 2002-10-17 | 2006-01-26 | Decode Genetics, Inc. | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment |
US20080293750A1 (en) * | 2002-10-17 | 2008-11-27 | Anna Helgadottir | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment |
SI21402A (sl) | 2003-02-12 | 2004-08-31 | LEK farmacevtska dru�ba d.d. | Obloženi delci in farmacevtske oblike |
GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
TW200526274A (en) * | 2003-07-21 | 2005-08-16 | Smithkline Beecham Plc | Pharmaceutical formulations |
CA2657076A1 (en) * | 2003-08-28 | 2005-03-17 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of rosuvastatin calcium |
UY28501A1 (es) | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
NZ545498A (en) * | 2003-09-12 | 2010-04-30 | Amgen Inc | Rapid dissolution formulation of a calcium receptor-active compound |
GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
CA2546701C (en) * | 2003-11-24 | 2010-07-27 | Teva Pharmaceutical Industries Ltd. | Crystalline ammonium salts of rosuvastatin |
WO2005056534A1 (en) * | 2003-12-02 | 2005-06-23 | Teva Pharmaceutical Industries Ltd. | Reference standard for characterization of rosuvastatin |
US20100216863A1 (en) * | 2004-01-30 | 2010-08-26 | Decode Genetics Ehf. | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment |
US8158362B2 (en) * | 2005-03-30 | 2012-04-17 | Decode Genetics Ehf. | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype |
TW201240679A (en) * | 2004-03-12 | 2012-10-16 | Capsugel Belgium Nv | Pharmaceutical formulations |
WO2005107722A2 (en) * | 2004-05-04 | 2005-11-17 | Rhodia Inc. | Directly compressible tricalcium phosphate |
GB0411378D0 (en) * | 2004-05-21 | 2004-06-23 | Astrazeneca Ab | Pharmaceutical compositions |
CN1323665C (zh) * | 2004-06-16 | 2007-07-04 | 鲁南制药集团股份有限公司 | 治疗高血脂症的组合物 |
WO2006017357A1 (en) * | 2004-07-13 | 2006-02-16 | Teva Pharmaceutical Industries Ltd. | A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step |
CA2573316A1 (en) * | 2004-08-06 | 2006-02-16 | Transform Pharmaceuticals, Inc. | Novel fenofibrate formulations and related methods of treatment |
US20070037979A1 (en) * | 2005-02-22 | 2007-02-15 | Valerie Niddam-Hildesheim | Preparation of rosuvastatin |
US20070167625A1 (en) * | 2005-02-22 | 2007-07-19 | Anna Balanov | Preparation of rosuvastatin |
JP4713574B2 (ja) * | 2005-02-22 | 2011-06-29 | テバ ファーマシューティカル インダストリーズ リミティド | ロスバスタチンアルキルエーテルを含まないロスバスタチンおよびその塩およびそれらを製造する方法 |
MX2008001597A (es) * | 2005-08-04 | 2008-04-04 | Transform Pharmaceuticals Inc | Formulaciones novedosas que comprenden fenofibrato y una estatina y metodos relacionados de tratamiento. |
EP1805148A2 (en) * | 2005-08-16 | 2007-07-11 | Teva Pharmaceutical Industries Ltd. | Crystalline rosuvastatin intermediate |
SI1928409T1 (sl) | 2005-09-12 | 2012-12-31 | Actelion Pharmaceuticals Ltd. | Stabilni farmacevtski sestavek, ki obsega pirimidin-sulfamid |
DK1944029T3 (da) * | 2005-10-31 | 2012-01-23 | Kowa Co | Farmaceutisk præparat med fremragende fotostabilitet |
CN101330919B (zh) * | 2005-12-20 | 2012-12-05 | 力奇制药公司 | 包含(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲磺酰基)氨基]嘧啶-5-基]-(3r,5s)-3,5-二羟基庚-6-烯酸的药物组合物 |
HU227696B1 (en) * | 2006-04-13 | 2011-12-28 | Egyt Gyogyszervegyeszeti Gyar | Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it |
WO2007125547A2 (en) * | 2006-05-03 | 2007-11-08 | Manne Satyanarayana Reddy | Novel process for statins and its pharmaceutically acceptable salts thereof |
HU227610B1 (en) * | 2006-09-18 | 2011-09-28 | Richter Gedeon Nyrt | Pharmaceutical compositions containing rosuvastatin potassium |
US8404841B2 (en) * | 2006-10-09 | 2013-03-26 | Msn Laboratories Limited | Process for the preparation of statins and their pharmaceutically acceptable salts thereof |
US20080249141A1 (en) * | 2007-04-06 | 2008-10-09 | Palepu Nageswara R | Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters |
CN101795684A (zh) * | 2007-04-09 | 2010-08-04 | 赛多斯有限责任公司 | 他汀类化合物与抗肥胖药的组合 |
US20080249156A1 (en) * | 2007-04-09 | 2008-10-09 | Palepu Nageswara R | Combinations of statins and anti-obesity agent and glitazones |
CN101336920B (zh) * | 2007-07-05 | 2013-06-05 | 江苏正大天晴药业股份有限公司 | 一种稳定的药物组合物 |
AU2009208610A1 (en) * | 2008-01-30 | 2009-08-06 | Lupin Limited | Modified release formulations of HMG CoA reductase inhibitors |
WO2009112870A1 (en) * | 2008-03-11 | 2009-09-17 | Belupo-Lijekovi I Kozmetika D.D. | Pharmaceutical composition comprising rosuvastatin calcium and magnesium carbonate hydroxide pentahydrate as a stabilizer |
WO2009143776A1 (zh) | 2008-05-27 | 2009-12-03 | 常州制药厂有限公司 | 瑞舒伐他汀钙盐的制备方法及其中间体 |
US20100074947A1 (en) * | 2008-06-13 | 2010-03-25 | Adrian Brown | Pharmaceutical Formulations |
EP2138165A1 (en) | 2008-06-27 | 2009-12-30 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising a statin |
EA024554B1 (ru) * | 2008-06-27 | 2016-09-30 | Крка, Товарна Здравил, Д.Д., Ново Место | Твердая лекарственная форма, содержащая розувастатин, и способ ее получения |
US20110098315A1 (en) * | 2008-06-27 | 2011-04-28 | Farhad Sayyad Farshi | Pharmaceutical compositions of rosuvastatin calcium |
PL386051A1 (pl) * | 2008-09-09 | 2010-03-15 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego |
HU230877B1 (hu) * | 2008-09-30 | 2018-11-29 | EGIS Gyógyszergyár NyR | Stabil kombinációs gyógyszerkészítmény |
MX344885B (es) * | 2008-11-10 | 2017-01-10 | Psicofarma S A De C V | Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido. |
WO2010089770A2 (en) | 2009-01-19 | 2010-08-12 | Msn Laboratories Limited | Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof |
TR200902077A2 (tr) | 2009-03-17 | 2010-01-21 | Sanovel İlaç San.Veti̇c.A.Ş. | Stabil rosuvastatin kompozisyonları |
US8470805B2 (en) * | 2009-04-30 | 2013-06-25 | Kaohsiung Medical University | Processes for preparing piperazinium salts of KMUP and use thereof |
TR200904341A2 (tr) | 2009-06-03 | 2010-12-21 | Bi̇lgi̇ç Mahmut | Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler. |
EP2464344A2 (en) | 2009-08-13 | 2012-06-20 | Synthon B.V. | Pharmaceutical tablet comprising rosuvastatin calcium |
WO2011086584A2 (en) | 2010-01-18 | 2011-07-21 | Msn Laboratories Limited | Improved process for the preparation of amide intermediates and their use thereof |
CN101766578B (zh) * | 2010-02-09 | 2011-06-08 | 鲁南贝特制药有限公司 | 一种含瑞舒伐他汀钙的片剂及其制备工艺 |
WO2011139256A2 (en) | 2010-05-04 | 2011-11-10 | Bilgic Mahmut | Stable rosuvastatin formulations |
TR201009397A2 (tr) | 2010-11-11 | 2012-05-21 | Bi̇lgi̇ç Mahmut | Rosuvastatin içeren farmasötik bileşimler. |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
TWI462739B (zh) | 2010-11-02 | 2014-12-01 | Univ Kaohsiung Medical | Sildenafil-同族物四級銨哌嗪鹽類之製備及醫療用途 |
EP2698159A4 (en) * | 2011-04-12 | 2014-11-05 | Sawai Seiyaku Kk | PITAVASTATE-CONTAINING PREPARATION AND METHOD OF MANUFACTURING THEREOF |
MY166449A (en) | 2011-05-20 | 2018-06-27 | Astrazeneca Uk Ltd | Pharmaceutical composition of rosuvastatin calcium |
RU2508109C2 (ru) * | 2011-05-27 | 2014-02-27 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Фармацевтическая композиция для лечения нарушений липидного обмена |
JP5818219B2 (ja) * | 2012-05-14 | 2015-11-18 | 塩野義製薬株式会社 | 6,7−不飽和−7−カルバモイルモルヒナン誘導体含有製剤 |
AR091706A1 (es) * | 2012-07-11 | 2015-02-25 | Teva Pharma | Formulaciones de laquinimod sin agentes alcalinizantes |
AU2014230304B2 (en) * | 2013-03-12 | 2018-07-05 | Lg Chem, Ltd. | Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor |
RO129060B1 (ro) | 2013-04-25 | 2014-11-28 | Antibiotice S.A. | Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă |
RU2547574C2 (ru) * | 2013-07-09 | 2015-04-10 | Общество с ограниченной ответственностью "Трейдсервис" | Лекарственная форма гиполипидемического действия и способ ее изготовления |
KR101597004B1 (ko) | 2013-07-25 | 2016-02-23 | 씨제이헬스케어 주식회사 | 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제 |
CN107072997A (zh) * | 2014-11-11 | 2017-08-18 | 盐野义制药株式会社 | 含有对光不稳定的药物的多层片剂 |
JP2016169198A (ja) * | 2015-03-13 | 2016-09-23 | 大原薬品工業株式会社 | ロスバスタチンカルシウムを含有する錠剤 |
JP6095176B2 (ja) * | 2015-04-24 | 2017-03-15 | 大原薬品工業株式会社 | ロスバスタチンカルシウムの光安定性が向上したフィルムコーティング錠剤 |
AU2016342374B2 (en) | 2015-10-23 | 2022-08-04 | Lyndra Therapeutics, Inc. | Gastric residence systems for sustained release of therapeutic agents and methods of use thereof |
US11992552B2 (en) | 2015-12-08 | 2024-05-28 | Lyndra Therapeutics, Inc. | Geometric configurations for gastric residence systems |
EP3243506A1 (en) | 2016-05-09 | 2017-11-15 | Adamed sp. z o.o. | Pharmaceutical composition |
CN110022861B (zh) | 2016-09-30 | 2024-06-28 | 林德拉治疗公司 | 用于金刚烷类药物缓释的胃驻留系统 |
CN107913257A (zh) * | 2016-10-10 | 2018-04-17 | 北京阜康仁生物制药科技有限公司 | 一种包含瑞舒伐他汀钙的药物组合物及其制备方法 |
US10600502B2 (en) | 2016-12-20 | 2020-03-24 | Astrazeneca Uk Ltd. | Systems and methods for dispensing a statin medication over the counter |
US12023406B2 (en) | 2017-06-09 | 2024-07-02 | Lyndra Therapeutics, Inc. | Gastric residence systems with release rate-modulating films |
JP2018027987A (ja) * | 2017-11-24 | 2018-02-22 | 共和薬品工業株式会社 | 医薬組成物 |
CN112274487A (zh) * | 2019-07-25 | 2021-01-29 | 北京福元医药股份有限公司 | 一种瑞舒伐他汀钙药物制剂 |
CN110638743B (zh) * | 2019-10-25 | 2023-03-28 | 乐普制药科技有限公司 | 一种含布立西坦的组合物 |
US20220008519A1 (en) | 2020-07-09 | 2022-01-13 | Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) | Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho |
GB2622822A (en) | 2022-09-28 | 2024-04-03 | Novumgen Ltd | A rapidly disintegrating tablet of rosuvastatin and its process of preparation |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2262229A (en) * | 1939-06-24 | 1941-11-11 | Interchem Corp | Pigment and method of preparation |
GB653026A (en) | 1947-07-02 | 1951-05-09 | Merck & Co Inc | Vitamin preparations |
US4743450A (en) | 1987-02-24 | 1988-05-10 | Warner-Lambert Company | Stabilized compositions |
US4929620A (en) * | 1987-12-10 | 1990-05-29 | Warner-Lambert Company | 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis |
NO890521L (no) | 1988-02-25 | 1989-08-28 | Bayer Ag | Substituerte pyrimidiner. |
US5030447A (en) | 1988-03-31 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
AU3214689A (en) * | 1988-10-06 | 1990-05-01 | Sandoz Ag | Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them |
US5004651A (en) | 1989-01-24 | 1991-04-02 | Abbott Laboratories | Stabilizing system for solid dosage forms |
US5130298A (en) | 1989-05-16 | 1992-07-14 | Ethicon, Inc. | Stabilized compositions containing epidermal growth factor |
EP0475482B1 (en) | 1990-09-13 | 1994-10-05 | Akzo Nobel N.V. | Stabilized solid chemical compositions |
JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
HU9203780D0 (en) | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
US5478832A (en) * | 1992-05-08 | 1995-12-26 | The Green Cross Corporation | Quinoline compounds |
DE69324504T2 (de) | 1993-01-19 | 1999-08-26 | Warner Lambert Co | Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren |
TW442301B (en) * | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
PT814782E (pt) * | 1995-12-22 | 2003-04-30 | Nissan Chemical Ind Ltd | Composicao farmaceutica estabilizada com um agente basico |
DE69713948D1 (de) * | 1996-04-23 | 2002-08-22 | Janssen Pharmaceutica Nv | Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid |
US6417196B1 (en) | 1998-06-05 | 2002-07-09 | Warner-Lambert Company | Stabilization of quinapril using magnesium oxide |
SI20109A (sl) | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
GB9900339D0 (en) | 1999-01-09 | 1999-02-24 | Zeneca Ltd | Chemical compounds |
US6150410A (en) | 1999-02-04 | 2000-11-21 | Abbott Laboratories | pH independent extended release pharmaceutical formulation |
GB0000710D0 (en) * | 1999-02-06 | 2000-03-08 | Zeneca Ltd | Drug combination |
GB0001662D0 (en) * | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
AR022462A1 (es) * | 1999-02-06 | 2002-09-04 | Astrazeneca Uk Ltd | Uso de un agente que disminuye el colesterol |
GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
WO2001054688A1 (en) | 2000-01-28 | 2001-08-02 | Merck & Co., Inc. | Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug |
-
2000
- 2000-01-26 GB GBGB0001621.2A patent/GB0001621D0/en not_active Ceased
- 2000-04-08 UA UA2002021419A patent/UA51853C2/uk unknown
- 2000-08-02 NL NL1015858A patent/NL1015858C2/nl not_active IP Right Cessation
- 2000-08-02 NL NL1015859A patent/NL1015859C2/nl not_active IP Right Cessation
- 2000-08-04 SE SE0002826A patent/SE523471C2/sv not_active IP Right Cessation
- 2000-08-04 JP JP2000237576A patent/JP4800467B2/ja not_active Expired - Lifetime
- 2000-08-04 CN CNB001224840A patent/CN1149997C/zh not_active Expired - Lifetime
- 2000-08-04 TW TW089115659A patent/TWI228050B/zh not_active IP Right Cessation
- 2000-08-04 YU YU52902A patent/YU52902A/sh unknown
- 2000-08-04 SK SK1178-2000A patent/SK283872B6/sk unknown
- 2000-08-04 ES ES200001999A patent/ES2171123B1/es not_active Expired - Fee Related
- 2000-08-04 CN CNB001224859A patent/CN100528161C/zh not_active Expired - Lifetime
- 2000-08-04 AR ARP000104057A patent/AR023624A1/es unknown
- 2000-08-04 NO NO20003967A patent/NO312434B1/no not_active IP Right Cessation
- 2000-08-04 BE BE2000/0492A patent/BE1013414A5/fr not_active IP Right Cessation
- 2000-08-04 PT PT102503A patent/PT102503B/pt active IP Right Grant
- 2000-08-04 FR FR0010334A patent/FR2795324B1/fr not_active Expired - Lifetime
- 2000-08-04 JP JP2000237575A patent/JP3267960B2/ja not_active Expired - Lifetime
- 2000-08-04 RU RU2002122752/15A patent/RU2264210C2/ru active
- 2000-08-04 FR FR0010333A patent/FR2804025B1/fr not_active Expired - Lifetime
- 2000-08-04 US US09/633,064 patent/US6316460B1/en not_active Expired - Lifetime
- 2000-08-04 NZ NZ531474A patent/NZ531474A/en not_active IP Right Cessation
- 2000-08-04 BE BE2000/0491A patent/BE1013413A3/fr not_active IP Right Cessation
- 2000-08-04 CN CNA200710088942XA patent/CN101028268A/zh active Pending
- 2000-08-04 TR TR2002/00270T patent/TR200200270T2/xx unknown
- 2000-08-04 AU AU2000264559A patent/AU2000264559A1/en not_active Abandoned
- 2000-08-04 CA CA002313783A patent/CA2313783C/en not_active Expired - Fee Related
- 2000-08-04 FI FI20001750A patent/FI121365B/sv not_active IP Right Cessation
- 2000-08-04 HU HU0003110A patent/HU222578B1/hu active IP Right Grant
- 2000-08-04 CZ CZ20070222A patent/CZ299105B6/cs not_active IP Right Cessation
- 2000-08-04 CZ CZ20002883A patent/CZ290167B6/cs not_active IP Right Cessation
- 2000-08-04 ME MEP-2008-338A patent/ME00191B/me unknown
- 2000-08-04 EE EEP200200052A patent/EE04990B1/xx unknown
- 2000-08-04 EP EP10180659A patent/EP2266540A1/en not_active Withdrawn
- 2000-08-04 CH CH01541/00A patent/CH691347A5/de not_active IP Right Cessation
- 2000-08-04 DE DE10038108A patent/DE10038108A1/de not_active Ceased
- 2000-08-04 AT AT0136100A patent/AT412063B/de not_active IP Right Cessation
- 2000-08-04 EE EEP200900047A patent/EE05586B1/xx unknown
- 2000-08-04 IL IL14787000A patent/IL147870A/xx active Protection Beyond IP Right Term
- 2000-08-04 NO NO20003968A patent/NO327675B1/no not_active IP Right Cessation
- 2000-08-04 EP EP14170807.3A patent/EP2774609A1/en not_active Withdrawn
- 2000-08-04 EP EP08165575A patent/EP2018853A1/en not_active Withdrawn
- 2000-08-04 DE DE10038110A patent/DE10038110B4/de not_active Expired - Lifetime
- 2000-08-04 CA CA2639407A patent/CA2639407C/en not_active Expired - Fee Related
- 2000-08-04 TR TR2002/01888T patent/TR200201888T2/xx unknown
- 2000-08-04 BR BR0003365-0A patent/BR0003365A/pt not_active Application Discontinuation
- 2000-08-04 MY MYPI20003568 patent/MY123650A/en unknown
- 2000-08-04 PL PL341853A patent/PL196808B1/pl unknown
- 2000-08-04 PL PL00341855A patent/PL341855A1/xx not_active IP Right Cessation
- 2000-08-04 HU HU0003111A patent/HUP0003111A3/hu unknown
- 2000-08-04 CH CH01542/00A patent/CH700184B1/de not_active IP Right Cessation
- 2000-08-04 DK DK200001170A patent/DK200001170A/da not_active Application Discontinuation
- 2000-08-04 ME MEP-337/08A patent/MEP33708A/xx unknown
- 2000-08-04 EP EP09171015A patent/EP2133070A1/en not_active Withdrawn
- 2000-08-04 UA UA2002086973A patent/UA77156C2/xx unknown
- 2000-08-04 GB GB0019028A patent/GB2358582B/en not_active Expired - Lifetime
- 2000-08-04 AT AT0136000A patent/AT412062B/de not_active IP Right Cessation
- 2000-08-04 SI SI200030065T patent/SI1223918T1/xx unknown
- 2000-08-04 IT IT2000TO000779A patent/ITTO20000779A1/it unknown
- 2000-08-04 NZ NZ519774A patent/NZ519774A/en not_active IP Right Cessation
- 2000-08-04 RS YU5202A patent/RS50201B/sr unknown
- 2000-08-04 BR BR0003364-2A patent/BR0003364A/pt active IP Right Grant
- 2000-08-04 AR ARP000104058A patent/AR025055A1/es unknown
- 2000-08-04 GB GB0019029A patent/GB2358583B/en not_active Expired - Lifetime
- 2000-08-04 PT PT00953283T patent/PT1223918E/pt unknown
- 2000-08-04 WO PCT/GB2000/003017 patent/WO2001054669A1/en active Application Filing
- 2000-08-04 AU AU51841/00A patent/AU738074B2/en not_active Expired
- 2000-08-04 SE SE0002827A patent/SE523481C2/sv not_active IP Right Cessation
- 2000-08-04 TR TR2007/01171T patent/TR200701171T2/xx unknown
- 2000-08-04 MY MYPI20003567A patent/MY122707A/en unknown
- 2000-08-04 DK DK200001171A patent/DK178242B1/da not_active IP Right Cessation
- 2000-08-04 RU RU2002103603/14A patent/RU2206324C1/ru active
- 2000-08-04 WO PCT/GB2000/003014 patent/WO2001054668A1/en active IP Right Grant
- 2000-08-04 AT AT00953283T patent/ATE232088T1/de active
- 2000-08-04 PT PT102504A patent/PT102504A/pt active IP Right Grant
- 2000-08-04 CZ CZ20002884A patent/CZ298411B6/cs not_active IP Right Cessation
- 2000-08-04 CA CA002315141A patent/CA2315141C/en not_active Expired - Fee Related
- 2000-08-04 AP APAP/P/2002/002591A patent/AP1879A/en active
- 2000-08-04 DK DK00953283T patent/DK1223918T3/da active
- 2000-08-04 KR KR1020000045228A patent/KR100698333B1/ko active IP Right Review Request
- 2000-08-04 ME MEP-2008-337A patent/ME00202B/me unknown
- 2000-08-04 DE DE60001371T patent/DE60001371T2/de not_active Expired - Lifetime
- 2000-08-04 FI FI20001749A patent/FI111806B/sv not_active IP Right Cessation
- 2000-08-04 ZA ZA200003997A patent/ZA200003997B/xx unknown
- 2000-08-04 EP EP00953283A patent/EP1223918B1/en not_active Expired - Lifetime
- 2000-08-04 IT IT2000TO000780A patent/ITTO20000780A1/it unknown
- 2000-08-04 IL IL15051300A patent/IL150513A0/xx unknown
- 2000-08-04 US US09/633,114 patent/US6548513B1/en not_active Expired - Fee Related
- 2000-08-04 ZA ZA200003998A patent/ZA200003998B/xx unknown
- 2000-08-04 AP APAP/P/2002/002409A patent/AP1449A/en active
- 2000-08-04 EE EEP200200411A patent/EE05221B1/xx unknown
- 2000-08-04 KR KR10-2000-0045229A patent/KR100388713B1/ko active IP Right Grant
- 2000-08-04 ES ES200001998A patent/ES2155043B1/es not_active Expired - Fee Related
- 2000-08-04 TW TW089115660A patent/TW553749B/zh not_active IP Right Cessation
- 2000-08-04 AU AU51842/00A patent/AU781269C/en not_active Revoked
- 2000-08-04 SK SK1179-2000A patent/SK11792000A3/sk not_active Application Discontinuation
- 2000-08-04 AU AU65800/00A patent/AU6580000A/en not_active Abandoned
- 2000-08-04 ME MEP-338/08A patent/MEP33808A/xx unknown
- 2000-08-04 EP EP00951701A patent/EP1251831A1/en not_active Withdrawn
-
2001
- 2001-10-31 HK HK01107603A patent/HK1036934A1/xx not_active IP Right Cessation
- 2001-10-31 HK HK01107604A patent/HK1036935A1/xx not_active IP Right Cessation
-
2002
- 2002-01-29 IS IS6254A patent/IS1940B/is unknown
- 2002-01-30 CR CR6568A patent/CR6568A/es unknown
- 2002-01-30 HR HR20020097A patent/HRP20020097B1/xx not_active IP Right Cessation
- 2002-02-06 BG BG106393A patent/BG65234B1/bg unknown
- 2002-04-17 HK HK02102911.0A patent/HK1040936B/zh not_active IP Right Cessation
- 2002-06-26 CR CR6687A patent/CR6687A/es not_active Application Discontinuation
- 2002-07-01 IL IL150513A patent/IL150513A/en unknown
- 2002-07-16 BG BG110353A patent/BG110353A/en unknown
- 2002-07-16 BG BG106926A patent/BG66168B1/bg unknown
- 2002-07-23 IS IS6480A patent/IS6480A/is unknown
- 2002-07-25 HR HR20020632A patent/HRP20020632B1/xx not_active IP Right Cessation
- 2002-12-03 HK HK02108790.3A patent/HK1047052A1/zh unknown
-
2003
- 2003-02-18 HK HK03101240.3A patent/HK1048950A1/zh unknown
- 2003-04-11 KR KR1020030022854A patent/KR20030036492A/ko active Search and Examination
-
2005
- 2005-06-02 AU AU2005202392A patent/AU2005202392C1/en not_active Expired
-
2007
- 2007-03-07 IS IS8620A patent/IS2805B/is unknown
- 2007-03-09 NO NO20071303A patent/NO327554B1/no not_active IP Right Cessation
- 2007-03-12 JP JP2007062353A patent/JP4800988B2/ja not_active Expired - Lifetime
- 2007-03-30 AR ARP070101365A patent/AR060248A2/es unknown
- 2007-06-20 CL CL2007001807A patent/CL2007001807A1/es unknown
- 2007-11-15 IL IL187416A patent/IL187416A0/en unknown
-
2008
- 2008-06-24 CR CR10114A patent/CR10114A/es not_active Application Discontinuation
- 2008-10-20 HR HR20080525A patent/HRP20080525A2/xx not_active Application Discontinuation
-
2009
- 2009-03-26 BG BG10110353A patent/BG66159B1/bg unknown
-
2010
- 2010-03-10 NO NO2010005C patent/NO2010005I1/no unknown
- 2010-06-10 FI FI20105657A patent/FI121589B/sv not_active IP Right Cessation
-
2015
- 2015-02-02 HK HK15101088.4A patent/HK1200368A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI111806B (sv) | Farmaceutiska kompositioner | |
CA2630704A1 (en) | Pharmaceutical composition | |
MXPA00007656A (en) | Pharmaceutical compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MA | Patent expired |